Company Overview More
Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson’s, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
CEO: --
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > GANX Gain Therapeutics > Detailed Quotes

GANX Gain Therapeutics

2.680+0.010+0.37%
Trading Session 05/16 11:52 ET
High
2.710
Open
2.690
Turnover
57.17K
Low
2.650
Pre Close
2.670
Volume
21.39K
Market Cap
31.85M
P/E(TTM)
Loss
52wk High
10.999
Shares
11.88M
P/E(Static)
Loss
52wk Low
2.530
Float Cap
23.46M
Bid/Ask %
33.33%
Historical High
17.930
Shs Float
8.75M
Volume Ratio
0.49
Historical Low
2.530
Dividend TTM
--
Div Yield TTM
--
P/B
0.91
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.24%
Amplitude
2.25%
Avg Price
2.672
Lot Size
1
Float Cap
23.46M
Bid/Ask %
33.33%
Historical High
17.930
Shs Float
8.75M
Volume Ratio
0.49
Historical Low
2.530
Dividend TTM
--
P/B
0.91
Dividend LFY
--
Turnover Ratio
0.24%
Amplitude
2.25%
Avg Price
2.672
Lot Size
1
Price Forecast

Loading...

News

Comment